Other

Merck posts strong first-quarter profit, but revenue light

Drugmaker Merck's first-quarter revenue rose 6 percent, driven by a huge jump in sales of cancer blockbuster Keytruda, but a $1.4 billion charge for starting a research partnership with Japanese drugmaker Eisai dragged down ...

Diseases, Conditions, Syndromes

Diabetes drug found no better than placebo at treating NAFLD

A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, ...

Other

Merck beats 1Q profit views with tight cost controls

Merck posted an 18 percent jump in first-quarter income, beating Wall Street expectations, as reduced spending on marketing, administration and research easily offset lower medicine sales outside the U.S.

page 3 from 14